Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

• Váldodahkkit: Joshua K. Kays (Dahkki), Safi Shahda (Dahkki), Melissa Stanley (Dahkki), Teresa M. Bell (Dahkki), Bert H. O'Neill (Dahkki), Marc D. Kohli (Dahkki), Marion E. Couch (Dahkki), Leonidas G. Koniaris (Dahkki), Teresa A. Zimmers (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2018-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Background By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan...